Dr. Gregory George MD PhD Joins Mesoblast Board
Mesoblast (Nasdaq:MESO; ASX:MSB) has appointed Dr. Gregory George MD PhD, the company's largest shareholder, to its Board of Directors. Dr. George, founder of SurgCenter Development, the largest privately owned ambulatory surgical center company in the US, brings his experience as a medical scientist and successful entrepreneur to the board.
Dr. George expressed his investment conviction in Mesoblast's technology and leadership, highlighting the potential of mesenchymal stem cells to treat various diseases. He emphasized his experience in implementing innovative treatments for musculoskeletal conditions and achieving success through operational excellence.
The appointment aligns with Mesoblast's transition towards becoming an efficient commercial organization, with Chair Jane Bell noting Dr. George's operational and strategic expertise will support the company's goal of becoming a major global commercial biotechnology company.
Mesoblast (Nasdaq:MESO; ASX:MSB) ha nominato il Dr. Gregory George MD PhD, il maggiore azionista dell'azienda, nel suo Consiglio di Amministrazione. Il Dr. George, fondatore di SurgCenter Development, la più grande azienda di centri chirurgici ambulatoriali di proprietà privata negli Stati Uniti, porta la sua esperienza come scienziato medico e imprenditore di successo nel consiglio.
Il Dr. George ha espresso la sua convinzione nell'investimento nella tecnologia e nella leadership di Mesoblast, evidenziando il potenziale delle cellule staminali mesenchimali nel trattamento di varie malattie. Ha sottolineato la sua esperienza nell'implementazione di trattamenti innovativi per le condizioni muscoloscheletriche e nel raggiungere il successo attraverso l'eccellenza operativa.
La nomina si allinea con la transizione di Mesoblast verso un'organizzazione commerciale efficiente, con la Presidente Jane Bell che nota come l'esperienza operativa e strategica del Dr. George supporterà l'obiettivo dell'azienda di diventare una grande azienda biotecnologica commerciale globale.
Mesoblast (Nasdaq:MESO; ASX:MSB) ha nombrado al Dr. Gregory George MD PhD, el mayor accionista de la compañía, en su Junta Directiva. El Dr. George, fundador de SurgCenter Development, la empresa de centros quirúrgicos ambulatorios más grande de propiedad privada en EE. UU., aporta su experiencia como científico médico y emprendedor exitoso a la junta.
El Dr. George expresó su convicción de inversión en la tecnología y liderazgo de Mesoblast, destacando el potencial de las células madre mesenquimatosas para tratar diversas enfermedades. Enfatizó su experiencia en la implementación de tratamientos innovadores para condiciones musculoesqueléticas y en alcanzar el éxito a través de la excelencia operativa.
La designación se alinea con la transición de Mesoblast hacia convertirse en una organización comercial eficiente, con la presidenta Jane Bell señalando que la experiencia operativa y estratégica del Dr. George apoyará el objetivo de la compañía de convertirse en una importante empresa biotecnológica comercial global.
Mesoblast (Nasdaq:MESO; ASX:MSB)는 회사의 최대 주주인 Dr. Gregory George MD PhD를 이사회에 임명했습니다. Dr. George는 미국에서 가장 큰 민간 소유의 외래 수술 센터 회사인 SurgCenter Development의 창립자로, 이사회에 의학 과학자이자 성공적인 기업가로서의 경험을 제공합니다.
Dr. George는 Mesoblast의 기술과 리더십에 대한 투자 확신을 표현하며, 다양한 질병을 치료하는 데 있어 중간엽 줄기 세포의 잠재력을 강조했습니다. 그는 근골격계 질환을 위한 혁신적인 치료법을 구현한 경험과 운영 우수성을 통해 성공을 거둔 점을 강조했습니다.
이번 임명은 Mesoblast가 효율적인 상업 조직으로 전환하는 데 부합하며, 의장인 Jane Bell은 Dr. George의 운영 및 전략적 전문성이 회사의 목표인 주요 글로벌 상업 생명공학 회사로 성장하는 데 기여할 것이라고 언급했습니다.
Mesoblast (Nasdaq:MESO; ASX:MSB) a nommé le Dr. Gregory George MD PhD, le plus grand actionnaire de l'entreprise, à son Conseil d'Administration. Le Dr. George, fondateur de SurgCenter Development, la plus grande entreprise de centres chirurgicaux ambulatoires privés aux États-Unis, apporte son expérience en tant que scientifique médical et entrepreneur à succès au conseil.
Le Dr. George a exprimé sa conviction d'investissement dans la technologie et le leadership de Mesoblast, soulignant le potentiel des cellules souches mésenchymateuses pour traiter diverses maladies. Il a souligné son expérience dans la mise en œuvre de traitements innovants pour les affections musculosquelettiques et le succès obtenu grâce à l'excellence opérationnelle.
La nomination s'inscrit dans la transition de Mesoblast vers une organisation commerciale efficace, la présidente Jane Bell notant que l'expertise opérationnelle et stratégique du Dr. George soutiendra l'objectif de l'entreprise de devenir une grande entreprise biopharmaceutique commerciale mondiale.
Mesoblast (Nasdaq:MESO; ASX:MSB) hat Dr. Gregory George MD PhD, den größten Aktionär des Unternehmens, in den Vorstand berufen. Dr. George, Gründer von SurgCenter Development, dem größten privat geführten ambulanten chirurgischen Zentrum in den USA, bringt seine Erfahrung als Mediziner und erfolgreicher Unternehmer in den Vorstand ein.
Dr. George äußerte sein Investitionsvertrauen in die Technologie und Führung von Mesoblast und hob das Potenzial von mesenchymalen Stammzellen zur Behandlung verschiedener Krankheiten hervor. Er betonte seine Erfahrung in der Implementierung innovativer Behandlungen für muskuloskelettale Erkrankungen und den Erfolg durch operationale Exzellenz.
Die Ernennung steht im Einklang mit Mesoblasts Übergang zu einer effizienten Handelsorganisation, wobei die Vorsitzende Jane Bell anmerkte, dass Dr. Georges operative und strategische Expertise das Ziel des Unternehmens, ein bedeutendes globales kommerzielles Biotechnologieunternehmen zu werden, unterstützen wird.
- Largest shareholder joins Board of Directors, showing confidence in company
- New director brings proven track record of building billion-dollar medical company
- Addition of operational expertise to support commercial transition
- None.
NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Dr. Gregory George MD PhD, Mesoblast’s largest shareholder, to its Board of Directors.
Dr. George founded and managed the largest privately owned ambulatory surgical center company in the United States, SurgCenter Development. Dr. George brings to the Board his background as a medical scientist with unique operational experience having built a start-up company in the medical field and turning it into a highly-efficient multi-billion-dollar commercial organization.
Mesoblast Founder and Chief Executive Dr. Silviu Itescu said, “Greg’s unique operational skills and insights will provide tremendous value as Mesoblast transitions to become an efficient commercial organization.”
Commenting on his appointment Dr. George said, “I invested in Mesoblast because of my conviction in the technology, Dr. Itescu’s scientific knowledge, vision, and leadership combined with the ability of mesenchymal stem cells to treat, and possibly cure, a wide array of disease processes. I believe in Mesoblast’s potential to create a paradigm shift in health care by blazing a new path forward and making the impossible possible.”
Dr. George added, “I have first-hand knowledge of how innovative treatments for musculoskeletal diseases such as arthritis and back pain can transform patient outcomes and be rapidly incorporated into commercial product offerings of outpatient centers. While our Surgical Center company did not have the advantage of having a unique product with a wide patent portfolio like Mesoblast, we succeeded through operational excellence, good communications, being proactive, and trying to always beat timelines.”
Chair Jane Bell welcomed Dr. George to the Board and said, “Greg brings not only a high conviction in Mesoblast and our therapies but additionally important operational and strategic dimensions to our Board that will facilitate our corporate goal of building a major global commercial biotechnology company.”
About Mesoblast
Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.
Mesoblast’s RYONCIL® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.
Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. RYONCIL is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.
About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications are expected to provide commercial protection extending through to at least 2041 in major markets.
About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.
Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast
Forward-Looking Statements
This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.
Release authorized by the Chief Executive.
For more information, please contact:
| Corporate Communications / Investors | Media – Global |
| Paul Hughes | Allison Worldwide |
| T: +61 3 9639 6036 | Emma Neal |
| E: investors@mesoblast.com | T: +1 603 545 4843 |
| E: emma.neal@allisonworldwide.com | |
| Media – Australia | |
| BlueDot Media | |
| Steve Dabkowski | |
| T: +61 419 880 486 | |
| E: steve@bluedot.net.au | |
FAQ
Who is Dr. Gregory George and why did he join Mesoblast's (MESO) Board?
What experience does Dr. George bring to Mesoblast (MESO)?
How will Dr. George's appointment impact Mesoblast's (MESO) commercial strategy?
What is Dr. George's view on Mesoblast's (MESO) technology and potential?
